Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3275-3279

  Xiong, Yu ^a   Lu, Qing Jun ^b   Zhao, Jing ^c   Wu, Guo Yang ^a  

^a XIAMEN UNIVERSITY   (China)

^b Binzhou Central Hospital   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; HCC; Metformin; MTOR; Signaling pathway

Indexed keywords

EID: 84873599613     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3275     Document Type: Article

References (32)

1. An D, Kewalramani G, Chan JK Y et al (2006). Diabetologia, 49, 2174-84.
2. Avila MA, Berasain C, Sangro B, et al (2006). New therapies for hepatocellular carcinoma. Oncogene, 25, 3866-84.
3. Bailey CJ, Turner RC (1996). Metformin. N Engl J Med, 334, 574-9.
4. Bolster DR, Crozier SJ, Kimball SR, et al (2002). AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through downregulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem, 277, 977-80.
5. Bowker SL, Majumdar SR, Veugelers P et al (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29, 254-8.
6. Buzzai M, Jones RG, Amaravadi RK (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 67, 6745-52.
7. Cantrell LA, Zhou C, Mendivil A, et al (2010). Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecologic Oncology, 116, 92-8.
8. Currie CJ, Poole CD, Gale EA (2009).The influence of glucose-lowering therapie on cancer risk in type 2 diabetes. Diabetologia, 52, 1766-77.
9. Daniels D, Grytdal S, Wasley A (2009). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ, 58, 1-27.
10. Dowling RJO, Zakikhani M, Fantus IG, et al (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res, 67, 10804-12.
11. Duncan B, Schmidt MI (2009). Metformin, cancer, alphabet soup, and the role of epidemiology in etiologic research. Diabetes Care, 32, 1748-50.
12. Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5.
13. Goodwin PJ, Stambolic V, Lemieux J, et al (2011). Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat, 126, 215-20.
14. Gotlieb WH, Saumet J, Beauchamp MC (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology, 110, 246-50.
15. Hidalgo M, Rowinsky EK (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, 6680-6.
16. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11.
17. Holland EC, Sonenberg N, Pandolfi PP, et al (2004). Signaling control of mRNA translation in cancer pathogenesis. Oncogene, 23, 3138-44.
18. Huang X, Wullschleger S, Shpiro N, et al (2008). Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J, 412, 211-21.
19. Kahn BB, Alquier T, Carling D, et al (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab, 1, 15-25.
20. Kalender A, Selvaraj A, Kim SY, et al (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab, 11, 390-401.
21. Lee MS, Hsu CC, Wahlqvist M, et al (2011). Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer, 11, 20.
22. Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5.
23. Li DH, Ching JS, Yeung M, et al (2009). Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology, 137, 482-8.
24. Sahra IB, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86.
25. Schneider MB, Matsuzaki H, Haorah J, et al (2001). Prenvention of pancreatic cancer induction in hamsters by metformin. Gastroenterology, 120, 1263-70.
26. Soranna D, Scotti L, Zambon A (2012). Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. The Oncologist, 17, 1083-7159.
27. Wang LW, Li ZS, Zou DW, et al (2008). Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol, 14, 7192-8.
28. Wright JL, Stanford JL (2009). Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study. Cancer Causes Control, 20, 1617-22.
29. Wullschleger S, Loewith R, Hall MN (2006). TOR signaling in growth and metabolism. Cell, 124, 471-84.
30. Yu Y, Sato JD (1999). MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol, 178, 235-46.
31. Zakikhani M, Dowling R, Fantus IG, et al (2006). Metformin Is an AMP Kinase-Dependent Growth Inhibitor for Breast Cancer Cells. Cancer Res, 66, 10269-73.
32. Zhu Z, Jiang W, Thompson MD, et al (2011). Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog, 10, 17.